Anteotech (ADO.AX) Stock Price
Anteotech Price
Revenue has compounded at 10.3% per year over the past 19 years to 1.03 M AUD. Anteotech's net margin stands at -657.7%, up from -692.1% several years earlier. Analysts set a median price target of 0.39 AUD, implying 1,838.0% above the current price. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 100% above its 52-week low.
Anteotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Anteotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Anteotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Anteotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Anteotech Price |
|---|---|
| 9/11/2026 | 0.02 AUD |
| 9/10/2026 | 0.02 AUD |
| 9/9/2026 | 0.02 AUD |
| 9/8/2026 | 0.02 AUD |
| 9/7/2026 | 0.02 AUD |
| 9/4/2026 | 0.02 AUD |
| 9/3/2026 | 0.02 AUD |
| 9/2/2026 | 0.02 AUD |
| 9/1/2026 | 0.02 AUD |
| 8/31/2026 | 0.02 AUD |
| 8/28/2026 | 0.02 AUD |
| 8/27/2026 | 0.02 AUD |
| 8/26/2026 | 0.02 AUD |
| 8/25/2026 | 0.02 AUD |
| 8/24/2026 | 0.02 AUD |
| 8/21/2026 | 0.02 AUD |
| 8/20/2026 | 0.02 AUD |
| 8/19/2026 | 0.02 AUD |
| 8/18/2026 | 0.02 AUD |
| 8/17/2026 | 0.02 AUD |
| 8/14/2026 | 0.02 AUD |
| 8/13/2026 | 0.02 AUD |
| 8/12/2026 | 0.02 AUD |
| 8/11/2026 | 0.02 AUD |
| 8/10/2026 | 0.02 AUD |
| 8/7/2026 | 0.02 AUD |
| 8/6/2026 | 0.02 AUD |
| 8/5/2026 | 0.02 AUD |
| 8/4/2026 | 0.02 AUD |
| 8/3/2026 | 0.02 AUD |
Anteotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Anteotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESB |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | 1.00 | – | 2.00 | 4.00 | 8.00 | 15.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 100.00 | 100.00 | 87.50 |
| – | – | – | – | – | – | – | – | – | – | 100.00 | – | 25.00 | 25.00 | 25.00 | 25.00 |
| 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.50 | 1.00 | 2.00 | 3.75 |
| -4.00 | -6.00 | -4.00 | -3.00 | -3.00 | -4.00 | -7.00 | -12.00 | -13.00 | -12.00 | -9.00 | – | -2.00 | -4.00 | -8.00 | -15.00 |
| – | – | – | – | – | – | – | – | – | – | -900.00 | – | -100.00 | -100.00 | -100.00 | -100.00 |
| -4.00 | -6.00 | -10.00 | -3.00 | -3.00 | -3.00 | -6.00 | -10.00 | -12.00 | -8.00 | -6.00 | -2.00 | – | – | – | – |
| 100.00 | 50.00 | 66.67 | -70.00 | – | – | 100.00 | 66.67 | 20.00 | -33.33 | -25.00 | -66.67 | – | – | – | – |
| 0.90 | 1.01 | 1.20 | 1.23 | 1.20 | 1.53 | 1.80 | 1.99 | 2.02 | 2.26 | 2.61 | 2.61 | 2.61 | 2.61 | 2.61 | 2.61 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Anteotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Anteotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Anteotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Anteotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Anteotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Anteotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Anteotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Anteotech business model & stock analysis
Anteotech SWOT Analysis
Strengths
Anteotech Ltd possesses several strengths that contribute to its success in the market. The company demonstrates strong technological capabilities, with expertise in developing innovative products. Additionally, Anteotech has an experienced and talented workforce, enabling them to efficiently execute projects and deliver high-quality solutions. Furthermore, the company has established a strong reputation within the industry, known for its reliability and customer-oriented approach.
Weaknesses
Despite its strengths, Anteotech Ltd faces certain weaknesses that can hinder its performance. One weakness is the lack of market diversification, as the company heavily relies on a limited number of clients or sectors. This dependency on a specific market segment exposes the company to higher risks in case of a downturn or market saturation. Additionally, Anteotech may face challenges in scaling up its operations due to limited financial resources or infrastructure constraints.
Opportunities
There are several potential opportunities that Anteotech Ltd can capitalize on to further its growth. One opportunity lies in expanding its product offerings or entering new markets, allowing the company to reach a wider customer base and increase revenue streams. Furthermore, Anteotech can leverage technological advancements to enhance its products or develop new solutions that cater to emerging market demands. Additionally, strategic partnerships or collaborations with other industry players can provide access to new resources, expertise, and market opportunities.
Threats
Anteotech Ltd operates in a competitive market where it faces various external threats that could impact its business. One major threat is the presence of well-established competitors who already have a strong market position. These competitors may have larger resources and brand equity, making it challenging for Anteotech to gain market share. Additionally, changes in government policies or regulations can pose threats, potentially affecting the company's operations or increasing compliance costs. Economic downturns or uncertainties can also impact customer spending patterns, potentially reducing demand for Anteotech's products.
Anteotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Anteotech historical P/E ratio, EBIT multiple, and P/S ratio
Anteotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Anteotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Anteotech stock splits
Current Anteotech forecasts and price targets in September 2026
Analyst Price Targets 2026Anteotech shareholder structure
| % | Name |
|---|---|
1.04330% | |
0.04998% |
Anteotech Executives and Management Board
10 members · avg. age 44 · 40 % women
Dr. Nobuyoshi Maeji
Chief Scientific Officer · since 2009
175,835.00 AUD
Management
Mr. David Radford
Chief Executive Officer, Managing Director
Mr. Andrew Cook
Chief Financial Officer, Company Secretary
Mr. Tom Milicevic
Acting Chief Financial Officer, Company Secretary
Ms. Katrina Byrne
Chief Operating Officer
Ms. Tsui Min Lian
Chief Marketing Officer
Board of Directors
Ms. Glenda McLoughlin (51)
Non-Executive Independent Director
Dr. Geoffrey Cumming
Non-Executive Independent Director · since 2009
Dr. Katherine Wood (37)
Non-Executive Independent Director
Mr. Ewen Crouch
Independent Non-Executive Chairman of the Board
Anteotech Supply Chain
Anteotech Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.43 | 0.42 | 0.73 |
Frequently asked questions about Anteotech
The business model of Anteotech Ltd is focused on developing and commercializing innovative diagnostic technologies. The company specializes in the creation of cutting-edge medical devices and solutions, particularly in the field of infectious diseases and rapid diagnostics. Anteotech Ltd aims to provide accurate and efficient diagnostic tools for various healthcare applications, with a particular emphasis on point-of-care testing. By leveraging its expertise and innovative approach, Anteotech Ltd is committed to improving healthcare outcomes and facilitating timely diagnosis globally.
Anteotech Ltd is primarily active in the biotechnology industry.
The main competitors of Anteotech Ltd in the market include companies like Company XYZ, Company ABC, and Company DEF. These companies are known for their expertise in the same industry and offer similar products and services as Anteotech Ltd. In a competitive market like this, Anteotech Ltd strives to differentiate itself by providing unique features, innovative solutions, and exceptional customer service to gain a competitive advantage. By closely monitoring the offerings and strategies of these competitors, Anteotech Ltd continuously adapts and improves its products and services to stay ahead in the market.
Anteotech Ltd is a leading biotechnology company based in Australia. Established in 2015, Anteotech focuses on developing and commercializing innovative diagnostic technologies. The company specializes in point-of-care tests for infectious diseases, including respiratory infections and sexually transmitted infections. Anteotech's proprietary technology, known as the AnteoBind™ platform, enables enhanced sensitivity and accuracy in disease detection. With a team of experienced scientists and strong partnerships, Anteotech is dedicated to revolutionizing the field of diagnostics and improving global health outcomes. By leveraging cutting-edge technology, Anteotech continues to expand its product portfolio and deliver breakthrough solutions for rapid and reliable disease diagnosis.
Anteotech Ltd has achieved several significant milestones. The company successfully developed and launched its groundbreaking diagnostic platform, the EuGeni. This platform offers rapid and accurate testing for various diseases and infections, including COVID-19. Anteotech Ltd also secured partnerships and collaborations with renowned organizations and research institutions, amplifying their reach and impact in the healthcare industry. Additionally, the company received regulatory approvals for its products, further validating their quality and effectiveness. With continued dedication to innovation and scientific advancements, Anteotech Ltd has positioned itself as a leader in the field of diagnostic technologies.
As of the current information available, Anteotech Ltd is primarily present in Australia and the United Kingdom.
Anteotech Ltd represents values of innovation, excellence, and integrity. As a leading company, Anteotech focuses on developing and delivering cutting-edge technologies and solutions. With a strong corporate philosophy, the company strives to enhance the quality of life by creating products that address diverse industry needs. By leveraging its expertise, Anteotech aims to make a positive impact in sectors such as healthcare, diagnostics, and biotechnology. The company's commitment to research and development, along with its customer-centric approach, ensures that it stays at the forefront of industry advancements. Anteotech Ltd's dedication to sustainability and social responsibility further reinforces its reputation as a trusted and forward-thinking organization.
Analysts currently set an average price target of 0.39 AUD for the Anteotech stock (median: 0.39 AUD), implying +1,838.0 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Anteotech stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Anteotech to generate revenue of 900,000.00 AUD and earnings per share of -0.00 AUD.
Converted at the current exchange rate, the Anteotech share trades at 0.01 EUR (0.02 AUD).
The Anteotech share (ADO.AX) is listed on 1 stock exchanges, including: ASX (ADO.AX).
AnteoTech Ltd is an Australian company specializing in the development and marketing of technologies and products for the diagnosis of infectious diseases, cancer, and other illnesses. The company was founded in 2015 and is headquartered in Brisbane, Australia. AnteoTech has a diversified business model that includes life sciences, diagnostics, and research. The life sciences division of AnteoTech focuses on developing technologies to improve diagnosis and testing methods. They offer a technology called AnteoBind, which enables the rapid and precise detection of specific molecules. They also provide test kits for specific infectious diseases such as HIV, Hepatitis C, and syphilis, which can be used by medical professionals, laboratories, and diagnostic facilities. Additionally, the company is currently developing COVID-19 tests. The diagnostics division of AnteoTech includes portable devices capable of quickly and reliably diagnosing diseases such as cancer and blood disorders. The company has developed a patented technology called AnteoBind, which enhances the sensitivity of these devices and provides more precise results. In the research division, AnteoTech offers its technology and solutions to laboratories and research facilities to advance research efforts. The research division also offers a range of services to support research and development in the life sciences field. AnteoTech has established a reputation in the industry by licensing its products and technologies to other companies and partners. The company has distribution partnerships with global companies and strategic partners to distribute its products and technologies worldwide. It has also established a number of strategic alliances with leading diagnostic and life science companies. Overall, AnteoTech has built a diversified business model that encompasses a wide range of products and technologies capable of improving the diagnosis of infectious diseases, cancer, and other illnesses. The company has gained recognition in the industry and is known for its patented technologies and ability to stay at the forefront of the market with new technologies in collaboration with other companies and partners.
The expected revenue of Anteotech is 900,000.00 AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Anteotech is -2.61 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Anteotech is currently -20.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Anteotech stock.
The price-to-sales ratio (P/S) of Anteotech is currently 58.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Anteotech stock.
The Eulerpool Quality Score for Anteotech is 4/10.
The ISIN of Anteotech is AU000000ADO8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Anteotech is A0RC8F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Anteotech is ADO.AX. The ticker symbol is used to trade Anteotech shares on the stock exchange.
Anteotech paid dividends every year for the past 0 years.
Anteotech is assigned to the 'Health' sector.
The dividends of Anteotech are distributed in AUD.
Anteotech stock
Anteotech Peer Group
Anteotech Ticker
Anteotech FIGI
All fundamentals and in-depth analysis of Anteotech
Our stock analysis for Anteotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anteotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.